Home Colorectal Cancer MDS Patients Fare Worse With Two Mutated Copies of TP53 Than One,...

MDS Patients Fare Worse With Two Mutated Copies of TP53 Than One, Research Shows


NEW YORK – It has long been established that mutations in TP53 — the gene most frequently altered across all cancer types — can be an important predictor of patients’ survival outcomes and response to treatment.

In myeloid dysplastic syndromes, for instance, TP53 mutations are associated with shorter overall survival, resistance to standard treatments, and the transformation of MDS into acute myeloid leukemia.

Get the full story with
Premium Access

Only $95 for the
first 90 days*

Premium Access gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try Premium Access now.

You may already have institutional access!

Check if I qualify.

Already a Precision Oncology News or 360Dx or GenomeWeb Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.


This site uses Akismet to reduce spam. Learn how your comment data is processed.